Skip to main content
. 2015 May 14;112(12):1966–1975. doi: 10.1038/bjc.2015.160

Figure 1.

Figure 1

(A) Colorectal cancer (CRC) disease-specific survival (DSS) of patients with microsatellite instable (MSI; n=111, green line) and with microsatellite stable (MSS) tumours (n=651, blue line). Five-year survival: MSI, 83.2%, MSS, 70.5%. Ten-year survival: MSI, 83.2% MSS, 65.0%. P=0.004 for log-rank test (Mantel–Cox). (B) Rectal cancer DSS of patients with BRAFV600E (n=8, green line) and wild-type BRAF tumours (BRAF wild type, n=185, blue line). Five-year survival: BRAF wild type, 73.3% BRAFV600E, 28.6%. Ten-year survival: BRAF wild type, 46.3% BRAFV600E, 0%. P<0.001 for log-rank test (Mantel–Cox). (C) Colorectal cancer DSS of subtypes according to the following combinations of MSI and BRAF status: MSI/BRAF wild type (n=44, yellow line), MSI/BRAFV600E (n=60, purple line), MSS/BRAF wild type (n=600, blue line), and MSS/BRAFV600E (n=34, green line). Five-year survival: MSI/BRAF wild type, 80.7% MSI/ BRAFV600E, 84.6% MSS/BRAF wild type, 72.8% MSS/BRAFV600E, 40.5%. P<0.001 for log-rank test (Mantel–Cox). (D) Colorectal cancer DSS of patients with stage I–II disease according to the following combinations of MSI and BRAF status: MSI/BRAF wild type (n=33, yellow line), MSI/BRAFV600E (n=35, purple line), MSS/BRAF wild type (n=329, blue line), and MSS/BRAFV600E (n=9, green line). Five-year survival: MSI/BRAF wild type 93.4% MSI/BRAFV600E 92.9% MSS/BRAF wild type 89.0% MSS/BRAFV600E 70.0%. P=0.031 for log-rank test (Mantel–Cox); MSS/BRAFV600E vs MSS/BRAF wild type.